IPO Journey
Sunshine Biopharma Inc.
IPO Date: May 19, 2026 · 3 filings tracked
Final Offer Terms
Ticker
SBFM
Exchange
The Nasdaq Capital Market
Offer Price
$0.50
Shares Offered
11,160,000
Estimated Proceeds
$5.6M
Expected Listing
May 19, 2026
Underwriters
Led by Aegis Capital Corp.
Filing Timeline
1
S-1
August 5, 2025
- Steady revenue generation from its Nora Pharma subsidiary, which sells 70 generic prescription drugs and OTC supplements in Canada.
- High-upside, early-stage biotech pipeline featuring an mRNA therapy for liver cancer and an antiviral drug for COVID-19.
2
S-1
May 12, 2026
- Generates steady revenue through its Canadian subsidiary, Nora Pharma, which sells 60 generic prescription drugs.
- Maintains a diversified business model combining generic drugs, over-the-counter supplements, and early-stage drug development.
Changes from previous filing
- ▸ Final offer price: $1.03 per share
- ▸ Shares offered: 5,825,242
- ▸ Estimated proceeds: $5M
- ▸ Underwriters: Aegis Capital Corp.
424B4
Final Pricing
May 19, 2026
- Dual-model business combining high-upside drug development with steady revenue from Nora Pharma
- Nora Pharma provides an established commercial footprint with 60 generic prescription drugs sold in Canada
Changes from previous filing
- ▸ Final offer price: $0.5 per share
- ▸ Shares offered: 11,160,000
- ▸ Estimated proceeds: $5M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.